Claims for Patent: 11,326,168

Summary for Patent: 11,326,168

Title:	Use of potassium channel inhibitor for treating depression
Abstract:	In light of a discovery that astroglial Kir4.1 in lateral habenula drives neuronal bursts in depression, the present disclosure provides a pharmaceutical agent and a method of use thereof for treating depression. The pharmaceutical agent can inhibit an activity of an astroglial potassium channel, and especially suppress expression or functionality of Kir4.1, in astrocytes in the lateral habenula of a subject so that bursting activity of neurons in the lateral habenula of the subject can be suppressed. The pharmaceutical agent can include a vector expressing a target nucleotide sequence in the astrocytes in the lateral habenula, whose expression is configured to suppress Kir4.1 expression by RNA interference, or to block Kir4.1 functionality by a dominant negative effect of a mutant Kir4.1 protein. The pharmaceutical agent can alternatively comprise a small molecule compound, or an active macromolecule such as an anti-Kir4.1 antibody, configured to directly inhibit the astroglial potassium channel activity.
Inventor(s):	Hailan HU, Yihui CUI, Yan Yang
Assignee:	Zhejiang University ZJU
Application Number:	US16/679,197

Details for Patent 11,326,168

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bluebird Bio Inc.	SKYSONA	elivaldogene autotemcel	Injection	125755	September 16, 2022	11,326,168	2039-11-09

International Patent Family for US Patent 11,326,168

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2018205927
United States of America	2023050684
United States of America	2020149051
European Patent Office	3622958